MIF-1 (Pro-Leu-Gly-NH₂, abbreviated PLG; melanostatin) is an endogenous tripeptide formed by cleavage of the C-terminal fragment of oxytocin. Its historical name is melanocyte-stimulating-hormone release-inhibiting factor 1. The best-documented pharmacological property of MIF-1 is positive allosteric modulation of dopamine D2 and D4 receptors.

Identity and physicochemical data

  • Sequence: H-Pro-Leu-Gly-NH₂ (amidated C-terminus)
  • Molecular formula: C₁₃H₂₄N₄O₃; molar mass ≈ 284.35 g/mol
  • CAS (Chemical Abstracts Service number): 2002-44-0 (free base); 35240-69-8 (trifluoroacetate, TFA salt)
  • Synonyms: melanostatin, MIF-1, PLG, MSH-release-inhibiting factor 1
  • Origin: C-terminal tripeptide fragment of oxytocin

Origin and place in the peptide family

MIF-1 belongs to the Tyr-MIF-1 family, short endogenous brain peptides that engage both opioid and non-opioid targets [8][9]. MIF-1 is unusually resistant to plasma peptidases and crosses the blood-brain barrier directly, so it reaches the CNS from the periphery [9].

Mechanism: allosteric modulation of dopamine D2/D4 receptors

MIF-1 acts as a positive allosteric modulator of the D2 and D4 dopamine receptor subtypes: it binds a site distinct from the orthosteric (agonist-binding) pocket and enhances the receptor's response to dopamine rather than activating the receptor directly. In behavioural models the effect of MIF-1 (for example, anti-immobility) is blocked by dopamine-receptor antagonists, pointing to a dopaminergic mechanism [5]. A series of MIF-1 peptidomimetics, more potent and metabolically stable D2 modulators, including PAOPA and proline-bioisostere analogues, have been developed and support and refine the allosteric model [6][7].

“Melanostatin”: historical context

The compound was originally isolated as a factor that inhibits release of melanocyte-stimulating hormone (MSH) from the intermediate lobe of the pituitary, hence the name “melanostatin” and its described ability to suppress MSH-driven melanin release [8]. This “melanostatin” activity is largely part of the peptide's early neuroendocrine history; modern work focuses on its dopaminergic role in the CNS.

Research in Parkinson's disease

Interest in MIF-1 in parkinsonism dates back to the 1970s. In an early clinical observation, intravenous PLG potentiated the effect of levodopa in humans [1]. Antiparkinsonian activity of MIF-1 and its analogues was later shown in a primate MPTP model (marmosets) [2]. Importantly, these are small, mostly decades-old studies with mixed results; MIF-1 is not an established treatment for Parkinson's disease, and there are no modern large randomised controlled trials.

Research in depression

MIF-1 has also been examined as a candidate antidepressant. A small pilot study reported improvement in major depression after low subcutaneous doses of MIF-1 [3]; activity was also seen in chronic-stress animal models [4]. Because the behavioural effect depends on dopamine receptors [5], it is attributed to dopaminergic modulation. Importantly, these are small, old pilot studies with mixed data; MIF-1 is not an approved antidepressant and its efficacy in humans is not established.

Limitations of the evidence

Much of the clinical data on MIF-1 comes from the 1970s-1990s, with small samples and without modern randomisation and blinding standards. The mechanistic picture (D2/D4 allosteric modulation) rests mainly on preclinical and medicinal-chemistry work. Any claim of therapeutic benefit in humans would therefore be premature. This monograph describes scientific identity and research directions, not clinical recommendations.

Status and intended use

This material is reference/scientific in nature. The reagent is supplied for laboratory research only (RUO): it is not a medicine, has no proven safety or efficacy, and is not intended for human or animal consumption, diagnosis or treatment. We do not provide dosing or usage protocols here.